I love being part of the THL team and contributing to our evolution.”

As a Finance Manager, Chris helps limited partners (LPs) reconcile their accounts, including capital calls, distributions and taxes, and also maintains the LP information portal. She is also a notary public who works closely with the firm’s Legal, Finance and Investor Relations groups.

Before joining the THL team, Chris worked at John Hancock Signature Services Life Insurance and Annuities and Zentropy Partners Web Interactive of Hill Holiday. Outside the office, she enjoys hosting and cooking for guests as well as outdoor activities like gardening and boating.

Related content

Forward Through Uncertainty: What Biopharma Leaders Are Saying About the FDA, R&D Investment
Insights
Forward Through Uncertainty: What Biopharma Leaders Are Saying About the FDA, R&D Investment 

Key Takeaways Recent FDA changes have generated uncertainty across the biopharma sector, with questions mounting around approval timelines, shifting trial expectations, and regulatory consistency. In May and June 2025, THL surveyed 100 biopharma decision-makers—spanning early-stage biotechs to top 50 pharma companies—to better understand how today’s regulatory and market dynamics are influencing R&D investment. Most respondents plan to maintain

Healthcare (HC)